Xencor, Inc. (XNCR)
24.94
+1.75
(+7.55%)
USD |
NASDAQ |
Oct 20, 16:00
25.19
+0.25
(+1.00%)
After-Hours: 07:25
Xencor Research and Development Expense (TTM) : 255.76M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 255.76M |
| March 31, 2026 | 245.52M |
| December 31, 2025 | 239.43M |
| September 30, 2025 | 225.67M |
| June 30, 2025 | 229.52M |
| March 31, 2025 | 229.39M |
| December 31, 2024 | 227.69M |
| September 30, 2024 | 239.68M |
| June 30, 2024 | 246.39M |
| March 31, 2024 | 244.92M |
| December 31, 2023 | 252.42M |
| September 30, 2023 | 240.83M |
| June 30, 2023 | 229.16M |
| March 31, 2023 | 216.19M |
| December 31, 2022 | 199.56M |
| September 30, 2022 | 199.10M |
| June 30, 2022 | 196.44M |
| March 31, 2022 | 198.85M |
| December 31, 2021 | 192.51M |
| September 30, 2021 | 189.47M |
| June 30, 2021 | 183.31M |
| March 31, 2021 | 177.27M |
| December 31, 2020 | 169.80M |
| September 30, 2020 | 149.19M |
| June 30, 2020 | 134.51M |
| Date | Value |
|---|---|
| March 31, 2020 | 124.35M |
| December 31, 2019 | 118.59M |
| September 30, 2019 | 118.38M |
| June 30, 2019 | 109.56M |
| March 31, 2019 | 99.60M |
| December 31, 2018 | 97.50M |
| September 30, 2018 | 90.77M |
| June 30, 2018 | 89.22M |
| March 31, 2018 | 82.81M |
| December 31, 2017 | 71.77M |
| September 30, 2017 | 64.74M |
| June 30, 2017 | 59.40M |
| March 31, 2017 | 56.88M |
| December 31, 2016 | 51.87M |
| September 30, 2016 | 49.39M |
| June 30, 2016 | 45.90M |
| March 31, 2016 | 38.97M |
| December 31, 2015 | 34.14M |
| September 30, 2015 | 28.32M |
| June 30, 2015 | 22.69M |
| March 31, 2015 | 19.49M |
| December 31, 2014 | 18.52M |
| September 30, 2014 | 17.61M |
| June 30, 2014 | 16.82M |
| March 31, 2014 | 16.48M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| UroGen Pharma Ltd. | 61.26M |
| MeiraGTx Holdings Plc | 153.16M |
| IDEAYA Biosciences, Inc. | 374.01M |
| Iovance Biotherapeutics, Inc. | 267.71M |